Affy's Sales Slide 7 Percent in Q1 as Charges Turn Profit to Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Affymetrix today said first-quarter revenues dropped 7 percent as R&D spending fell 16 and a profit turned to a loss on restructuring charges.
 
Total receipts for the three months ended March 31 fell to $80.4 million from $86.4 million year over year.
 
Product and product-related revenue decreased 10 percent to $71.3 million; royalties and "other" revenue increased 33 percent to $2.4 million; and receipts from Perlegen rose 26 percent to $6.7 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.